Healthcare Industry News: kidney disease
News Release - August 23, 2007
Cytochroma announces appointment of Gordon Ngan, CFA, MBA as Executive Director, Corporate DevelopmentMARKHAM, ON, Aug. 23 (HSMN NewsFeed) - Cytochroma Inc. announced today that Mr. Gordon Ngan has joined Cytochroma's management team as Executive Director, Corporate Development. Mr. Ngan will be responsible for coordinating corporate finance and related investor activities, as well as securing corporate partnerships with firms focused on the chronic kidney disease (CKD) market.
Mr. Ngan brings to Cytochroma more than 10 years of finance, capital markets, investor relations, and business development experience. Most recently, Mr. Ngan was Associate Analyst, Biotechnology and Pharmaceuticals for the Equity Research group at National Bank Financial where he was involved in identifying and researching promising healthcare companies. Previous to his experiences on the sellside, he held a number of industry roles at BioChem Pharma and Shire Pharmaceuticals Group plc, including Head of North American Investor Relations, and then Global Head of Investor Relations, followed by a role in business development at Shire's UK headquarters. In this latter role, Mr. Ngan worked on a number of successful partnership deals in the renal, hematology, and CNS fields.
"We are pleased to welcome Gordon to the management team at Cytochroma," said Charles W. Bishop, PhD, President and CEO. "We intend to further develop Cytochroma's capital markets and investor strategy and Gordon brings valuable experience and a unique perspective that will play a critical role in achieving this goal."
"Cytochroma has an experienced management team which has built a remarkable portfolio of renal products addressing clear areas of unmet medical need and has established strong relationships with key opinion leaders in the scientific and clinical community. I am delighted to join Cytochroma at this exciting stage of the Company's development," stated Mr. Ngan. "I look forward to working with investors and corporate partners to rapidly grow the company and advance its products."
About Cytochroma Inc.
Cytochroma (www.cytochroma.com) is a specialty pharmaceutical company engaged in the development and commercialization of proprietary products to treat and prevent the clinical consequences of Vitamin D insufficiency. The Company has an advanced portfolio of new therapies for Vitamin D insufficiency and secondary hyperparathyroidism associated with CKD. In addition, the Company is developing novel therapies to treat hyperproliferative disorders, such as cancer and psoriasis, and hyperphosphatemia.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.